|
Patent landscape, scope, and claims: |
United States Patent 7,361,650: Scope, Claims, and Landscape Analysis
United States Patent 7,361,650, titled "Method of Treating Hypercholesterolemia and Hyperlipidemia," issued on April 22, 2008, to Merck & Co., Inc. The patent covers a method of treating hypercholesterolemia and hyperlipidemia by administering a specific dosage of ezetimibe. Ezetimibe, marketed as Zetia and co-marketed as Vytorin (with simvastatin), is a cholesterol absorption inhibitor. This analysis examines the patent's core claims, its scope, and its position within the broader drug patent landscape, providing insights for stakeholders in the pharmaceutical sector.
What is the Core Technology Protected by Patent 7,361,650?
Patent 7,361,650 protects a specific method of medical treatment. The primary claims focus on the administration of ezetimibe, a distinct chemical entity, for therapeutic purposes.
What are the Key Claims?
The patent's independent claims are directed to methods of treatment.
-
Claim 1: This is the central claim. It recites a method for treating hypercholesterolemia and/or hyperlipidemia. The method involves administering to a subject a dosage of ezetimibe in an amount of about 10 mg once daily. The claim specifies that the subject is one in which plasma cholesterol levels are to be reduced. The patent defines ezetimibe as 1-(4-fluorophenyl)-3(R)-[3(S)-4-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-(4-hydroxy-phenyl)-azetidin-2-one.
-
Claim 2: This claim depends on Claim 1. It further defines the treatment method by specifying that the subject is one who has been administered a statin therapy.
-
Claim 3: This claim also depends on Claim 1. It specifies that the subject is one who has been administered a statin therapy and is receiving a dosage of ezetimibe in an amount of about 10 mg once daily.
-
Claim 4: This claim depends on Claim 1. It specifies that the subject is one who has been administered a statin therapy and is receiving a dosage of ezetimibe in an amount of about 10 mg once daily, in combination with a statin.
-
Claim 5: This claim depends on Claim 1. It specifies that the subject is one who has been administered a statin therapy and is receiving a dosage of ezetimibe in an amount of about 10 mg once daily, in combination with a statin, where the statin is selected from the group consisting of simvastatin, atorvastatin, rosuvastatin, pravastatin, fluvastatin, lovastatin, and pitavastatin.
-
Claim 6: This claim depends on Claim 1. It specifies that the subject is one who has been administered a statin therapy and is receiving a dosage of ezetimibe in an amount of about 10 mg once daily, in combination with a statin, where the statin is simvastatin.
-
Claim 7: This claim depends on Claim 1. It specifies that the subject is one who has been administered a statin therapy and is receiving a dosage of ezetimibe in an amount of about 10 mg once daily, in combination with a statin, where the statin is administered in a dosage range of 10 mg to 80 mg daily.
-
Claim 8: This claim depends on Claim 1. It specifies that the subject is one who has been administered a statin therapy and is receiving a dosage of ezetimibe in an amount of about 10 mg once daily, in combination with a statin, where the statin is administered in a dosage range of 20 mg to 40 mg daily.
-
Claim 9: This claim depends on Claim 1. It specifies that the subject is one who has been administered a statin therapy and is receiving a dosage of ezetimibe in an amount of about 10 mg once daily, in combination with a statin, where the statin is administered in a dosage range of 10 mg to 20 mg daily.
-
Claim 10: This claim depends on Claim 1. It specifies that the subject is one who has been administered a statin therapy and is receiving a dosage of ezetimibe in an amount of about 10 mg once daily, in combination with a statin, where the statin is administered in a dosage range of 5 mg to 10 mg daily.
-
Claim 11: This claim depends on Claim 1. It specifies that the subject is one who has been administered a statin therapy and is receiving a dosage of ezetimibe in an amount of about 10 mg once daily, in combination with a statin, where the statin is administered in a dosage range of 5 mg to 40 mg daily.
-
Claim 12: This claim depends on Claim 1. It specifies that the subject is one who has been administered a statin therapy and is receiving a dosage of ezetimibe in an amount of about 10 mg once daily, in combination with a statin, where the statin is administered in a dosage range of 20 mg to 80 mg daily.
What is the Defined Chemical Structure?
The patent provides the following chemical name for ezetimibe: 1-(4-fluorophenyl)-3(R)-[3(S)-4-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-(4-hydroxy-phenyl)-azetidin-2-one.
What is the Targeted Dosage and Frequency?
The patent specifically claims the administration of ezetimibe in an amount of "about 10 mg once daily."
What Conditions are Treated?
The protected methods are for treating hypercholesterolemia and/or hyperlipidemia.
What is the Scope of Protection?
The scope of Patent 7,361,650 is defined by its claims, which are directed towards a method of treatment rather than the composition of matter of ezetimibe itself.
What is the Relationship to the Active Pharmaceutical Ingredient (API)?
While the patent claims a method of using ezetimibe, the API itself is protected by other patents. For instance, US Patent 5,756,470, also assigned to Merck, claims the compound ezetimibe. Patent 7,361,650 builds upon the availability of ezetimibe by defining specific therapeutic regimens.
What is the Significance of "About 10 mg"?
The inclusion of "about 10 mg" provides some latitude in the dosage. This phrase is common in patent claims and typically allows for minor variations that do not fundamentally alter the claimed method. Courts often interpret "about" in the context of the specification and prosecution history.
What is the Importance of Combination Therapy?
Several claims (Claims 2 through 12) explicitly mention combination therapy with statins. This indicates a focus on using ezetimibe in conjunction with existing lipid-lowering drugs, a common strategy in managing cardiovascular risk factors. The claims detail specific statin classes and dosage ranges, narrowing the scope but also providing clarity on intended applications.
What is the Patent Landscape for Ezetimibe?
The patent landscape surrounding ezetimibe is characterized by multiple patents covering the compound, its synthesis, formulations, and methods of use, alongside significant patent litigation and the eventual expiry of key patents leading to generic competition.
What are the Key Ezetimibe Patents?
-
US Patent 5,756,470: This patent, also assigned to Merck, claims the compound ezetimibe. It is a foundational patent for the drug. This patent expired on October 18, 2016, after a 20-year term from its filing date of October 18, 1996.
-
US Patent 7,361,650: The subject of this analysis, this patent claims specific methods of treating hypercholesterolemia and hyperlipidemia using ezetimibe, particularly in combination with statins. Its term is 20 years from its filing date, December 20, 2005, meaning it expired on December 20, 2025.
-
Other Patents: Numerous other patents exist related to ezetimibe, covering various formulations, manufacturing processes, and therapeutic indications. For example, patents relating to crystalline forms of ezetimibe and specific pharmaceutical compositions were also filed.
What is the Role of Formulation Patents?
Formulation patents can extend market exclusivity. Patents covering specific polymorphic forms of ezetimibe or unique drug delivery systems can provide additional layers of protection. However, the primary method of use patent (7,361,650) and the compound patent (5,756,470) are critical for market exclusivity.
What are the Historical Patent Challenges and Litigation?
Ezetimibe's patent protection has been the subject of extensive litigation. Generic manufacturers have challenged the validity and enforceability of Merck's patents, particularly the compound patent and formulation patents, leading to numerous court battles. These challenges often focus on obviousness, enablement, and anticipation.
What is the Impact of Patent Expiry on Market Dynamics?
The expiry of the core ezetimibe compound patent (US 5,756,470) in October 2016 opened the door for generic ezetimibe entry into the market. Subsequent generic competition intensified following the expiry of related formulation and method of use patents. This typically leads to significant price erosion and a shift in market share towards lower-cost generic alternatives.
What is the Competitive Landscape for Ezetimibe?
Prior to patent expiries, the primary competition for ezetimibe came from other cholesterol-lowering drugs, primarily statins, and combination therapies. With generic entry, competition shifted to include multiple generic manufacturers of ezetimibe and ezetimibe/statin combination products.
What is the Status of Patent 7,361,650?
Patent 7,361,650 issued on April 22, 2008, with a filing date of December 20, 2005. As a utility patent claiming a method of treatment, its term is 20 years from the filing date.
What is the Patent Term Expiry Date?
Based on the filing date of December 20, 2005, Patent 7,361,650 expired on December 20, 2025.
What is the Impact of Expiry on Future Market Access?
The expiry of Patent 7,361,650 means that the specific method of treatment claimed (administration of about 10 mg ezetimibe once daily, particularly in combination with statins) is no longer protected by this patent. This allows for the widespread use and generic marketing of ezetimibe for these indications without infringing this particular patent.
Is the Patent Still Enforced?
Given that the patent term has expired, it can no longer be enforced against new infringements. Any potential past infringements would have had to be pursued before the expiry date.
Key Takeaways
- Core Protection: United States Patent 7,361,650 protects specific methods of treating hypercholesterolemia and hyperlipidemia using ezetimibe, particularly at a dosage of approximately 10 mg daily, and especially when combined with statin therapy.
- Method of Use Claim: The patent's claims are directed to therapeutic methods, not the ezetimibe compound itself, which is covered by earlier patents.
- Combination Therapy Focus: A significant portion of the claims emphasizes the use of ezetimibe in combination with various statins and dosage ranges.
- Patent Term: The patent expired on December 20, 2025, marking the end of its 20-year term from the filing date.
- Market Impact: Patent expiry removes the method-of-use restriction, facilitating broader generic use and market competition for ezetimibe in the claimed therapeutic areas.
- Landscape Context: This patent is one of several covering ezetimibe, with its compound patent expiring earlier and paving the way for generic entry. Litigation has been a significant aspect of the ezetimibe patent landscape.
Frequently Asked Questions
-
Does patent 7,361,650 cover the ezetimibe drug itself?
No, Patent 7,361,650 claims a method of treating specific medical conditions using ezetimibe. The ezetimibe compound itself was protected by earlier patents, such as U.S. Patent 5,756,470.
-
When did patent 7,361,650 expire, and what is the consequence of this expiry?
Patent 7,361,650 expired on December 20, 2025. This means that the specific method of treatment claims in this patent are no longer protected, allowing for wider use of ezetimibe in the claimed therapeutic regimens without infringing this patent.
-
What is the significance of the "about 10 mg once daily" dosage in the patent claims?
This phrase defines a specific therapeutic regimen. The term "about" allows for minor variations in the dosage, and the "once daily" frequency specifies the administration schedule. This level of detail is crucial for defining the scope of the method of treatment.
-
Are there any ongoing legal disputes related to patent 7,361,650?
As of its expiry date, Patent 7,361,650 can no longer be enforced for new infringements. Any past disputes would have needed to be resolved before the patent term ended.
-
How does patent 7,361,650 relate to combination therapies involving ezetimibe and statins?
Several claims within Patent 7,361,650 specifically cover methods of treatment where ezetimibe is administered in combination with statins, including details on specific statin classes and dosage ranges. This indicates a strategic focus on protecting the use of ezetimibe as an adjunct therapy for lipid management.
Citations
[1] Merck & Co., Inc. (2008). United States Patent 7,361,650: Method of treating hypercholesterolemia and hyperlipidemia. Retrieved from United States Patent and Trademark Office.
[2] Merck & Co., Inc. (1998). United States Patent 5,756,470: Azetidinone derivatives. Retrieved from United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
